TLR4 and Hepatic fibrosis: These agents protected against hepatic fibrosis through two different mechanisms: (i) influencing HSCs (activating LPS-TLR4 signaling), and (ii) targeting the intestinal barrier (intestinal tight junction protein), decreasing intestinal permeability and consequently portal endotoxin levels.